Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

From:
Department for International Development
Published
1 January 2010
Country:
Uganda
Document Type:
Journal Article
Theme:
Health
Authors:
Grosskurth, H., Walker, A.S., Kityo, C., Gilks, C.F., Mugyenyi, P., Munderi, P., Gibb, D.M., Ssali, F., Reid, A., Darbyshire, J.H., Babiker, A.G.

Abstract

Background: Triple nucleoside reverse transcriptase inhibitor regimens have advantages as first-line antiretroviral therapy (ART), avoiding hepatotoxicity and interactions with anti-tuberculosis therapy, and sparing two drug classes for second-line ART. Concerns exist about virological potency; efficacy has not been assessed in Africa. Methods: A safety trial comparing nevirapine with abacavir was conducted in two Ugandan Development of Antiretroviral Therapy in Africa (DART) centres: 600 symptomatic antiretroviral-naïve HIV-infected adults with CD4 counts

Citation

HIV Medicine (2010) 11 (5) 334 - 344 [DOI:10.1111/j.1468-1293.2009.00786.x].

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Updates to this page

Published 1 January 2010
Contents